Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Precision Biosciences Inc
(NQ:
DTIL
)
10.45
-0.04 (-0.33%)
Streaming Delayed Price
Updated: 12:51 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Precision Biosciences Inc
< Previous
1
2
3
4
Next >
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
May 01, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
April 16, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
March 27, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
March 20, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
March 19, 2024
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
March 06, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
March 01, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
February 29, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
February 20, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
February 14, 2024
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
February 13, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
February 12, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Effect a Reverse Stock Split
February 09, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
January 09, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
December 13, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
December 04, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Hep-DART 2023
November 30, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 28, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
November 14, 2023
Via
ACCESSWIRE
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
November 13, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Upcoming Sidoti Conference
November 10, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
November 09, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Third Quarter Results on November 7, 2023
November 01, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
October 26, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
October 23, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
October 12, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
September 27, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
September 12, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
September 06, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.